Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC.
OpenAlex 토픽 ·
Protein Kinase Regulation and GTPase Signaling
Lung Cancer Treatments and Mutations
Melanoma and MAPK Pathways
In a phase I/II clinical trial, patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer treated with the next-generation KRASG12C inhibitor elisrasib showed robust and
APA
(2026). Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC.. Cancer discovery, OF1. https://doi.org/10.1158/2159-8290.CD-NW2026-0041
MLA
. "Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC.." Cancer discovery, 2026, pp. OF1.
PMID
42010749
Abstract
In a phase I/II clinical trial, patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer treated with the next-generation KRASG12C inhibitor elisrasib showed robust and durable clinical responses. Patients naïve to KRASG12C inhibitors, as well as those refractory to other such drugs, experienced high rates of disease control-98.5% and 83.9%, respectively.